Safety and Efficacy of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-cell Therapy, in relapsed/refractory Multiple Myeloma: Preliminary Results from the DURGA-1 phase 1b/2 Study

Key Points

• AZD0120 shows potential efficacy in treating relapsed/refractory multiple myeloma, enhancing therapeutic options.
• Safety assessments reveal manageable adverse effects in the observed cohort of treated individuals.
• This phase 1b/2 study explores changes from prior therapies, revealing new response patterns to the dual-targeting approach.
• The findings may support further clinical trials and development of advanced CAR T-cell therapies for multiple myeloma.